FDA Issues Final Guidance On Morcellators Linked To Deadly Cancer Risk
The FDA's final guidance on power morcellators calls for them to only be used on younger women not suspected of having cancer, and only with the use of an approved…
The FDA's final guidance on power morcellators calls for them to only be used on younger women not suspected of having cancer, and only with the use of an approved…
The FDA has issued a new draft guidance on the use of power morcellators linked to the spread of undiagnosed cancers, indicating they should only be used with adequate containment…
A new study finds that women with uterine sarcoma who undergo morcellation face a significantly higher risk of death.
The CDC is considering a review of how gynecologists evaluate women for hidden uterine cancer and other sarcomas, which may result in new guidelines.
European regulators are raising concerns that the uterine fibroid drug Esmya, awaiting approval in the U.S., may be linked to liver damage and liver failure risks.
This is the list of the top 10 drug warnings and side effects of 2017, including warnings about breast implant cancer risks, gadolinium contrast agents and other unexpected complications.
The FDA reports that risks of contracting uterine cancer from power morcellation could be as high as 1-in-225, and also warns that cancer spread through morcellation appears to be more…
A new editorial say failures to more quickly identify and react to power morcellator cancer risk were in part due to a lack of a sound post-marketing surveillance system to…
A long-ignored technique known as embolization may be an under-used means of uterine fibroid removal, according to a new study. which comes as the medical community abandons morcellation procedures due…
A public workshop is being held today by the FDA to discuss improving reporting by hospitals on potentially dangerous medical devices after a number of incidents where hospitals knew devices…